Status: Recruiting
A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3H-10000 in the treatment of unresectable or metastatic solid tumors .
Participants needed: 170
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: 3H Pharmaceuticals Co., Ltd.Updated: Jan 21, 2026Locations: 1
Eligibility criteria
Subjects must be willing and able to sign the ICF and to adhere to the study vis... [+4]
Meningeal diseases or carcinomatous meningitis. [+4]